A~Tiybrid gene containing rabbit p*globin structural sequences (*9 to +1650), and a chicken conaibumin gene promoter (+62 to *102) in the place of the p-»globin promoter (upstream from * 9 ) , was inactive in 5 different trans* genie mouse l i n e . Adding the mouse immunoglobulin heavy»chain (IgH) enhancer to this construction specifically stimulated expression in B*cells. These results show that IgH enhancer is specifically active in B*cells. Expression of the hybrid gene was low compared to the endogenous immunoglobulin heavy and 11ght*chain genes. Substituting the mouse immunoglobulin < Iight*cha1n gene (Ig < ) promoter (+4 to *800) for the heterologous conalbumin promoter was not s u f f i c i e n t to restore gene expression to level of the endogenous genes. In addition to the reproducible B cell expression, we also found inhe* r i t a b l e unexpected expression in certain tissues, which varied from l i n e to l i n e .
INTRODUCTION
Transgenic mice can be used to study gene regulatory elements, as well as oncogenicity and control mechanisms such as a l l e l i c exclusion (Reviews: 1*4). In p a r t i c u l a r , i t has been shown that the rearranged mouse immunoglobu* l i n heavy* and 11ght*chain genes are expressed at high levels in specific tissues in transgenic mice ( specific expression in B lymphocytes. Nevertheless, replacing the conalbumin promoter by a Ig < promoter apparently results in higher specific expression. These results show that in transgenic mice the IgH enhancer is sufficient to specifically stimulate transcription in EMymphocytes, and suggests that an immunoglobulin promoter element can increase the level of specific expression.
MATERIALS AND METHODS

Construction of recombinants and microinjection.
A lkb Xbal DNA fragment, containing the mouse IgH enhancer (for sequence, see 11, 12) was Inserted into the Xbal site of the M13mpl2 polylinker j u s t upstream from the conalbumin promoter of ppCT (13) to give P6CTM. To construct pp<M, a Nsil (trimmed with T4 DNA polymerase and ligated to Hind I I I linkers)-*BglII fragment from the MPC11 < lights-chain gene promoter was used to replace the Hind I I I (+62) •••BamHI (^102) conalbumin fragment of ppCTM. Standard techniques were used (14) . Microinjections were performed as discussed in Brinster et a l . (15) .
B and T^cells p u r i f i c a t i o n . B and T*cells were purified from spleens of the 71 and 106 ppCTM trans* genie mouse lines as described in Mi shell and Shi i gi (16) . A single cell suspension from 2 spleens from each line was treated with 15mM Tris^HCl pH 7.2, 0.14M NH4C1 to lyse red»blood cells and adherent cells were removed by attachment to plastic culture flasks. Remaining cells were verified for via* b i l i t y with trypan blue and divided into aliquots. One aliquot was enriched for T^cell by panning out B*cells with anti*mouse Ig (Biosys). The y i e l d of T*cells was about 15%, and no more than 5% of these cells were Ig positive (as determined by immunofluorescence). B*cells were purified from another aliquot by selectively removing T»cells with anti thyl.2 (rat IgG 2b, Becton Dickinson) and rabbit complement (Gibco). The y i e l d of B^cells was about 15% and 90% of the cells were Ig positive.
RNA analysis. Total RNA was isolated from tissues with LiCl and urea (17) and from isolated B and T»cells with hot phenol (18) . RNA was analysed by quantitative SI nuclease mapping as described previously (19) . proportional to the number of cells with IgH enhancer a c t i v i t y . ppCT is not detectably expressed in several different tissues nor in reticulocytes of the 5 mouse lines containing the hybrid gene (see f1g.3C for examples with mouse lines 35 and 44). In addition to the tissues shown, there was no detectable expression in the following tissues: line 34, l i v e r , spleen, reticulocytes; l i n e 35, heart, intestine, brain and reticulocytes; line 37, l i v e r , spleen, kidney, brain, heart, thymus, testes and reticulocytes; line 44, brain, thymus, kidney, intestine; line 46, l i v e r , spleen, intestine, kidney, testes, brain and reticulocytes (results not shown). The recombinant containing in addition the IgH enhancer (ppCTM) was expressed specifically in organs containing lymphoid c e l l s , in particular the spleen (see lines 71, 106 and 91 in fig.3A , B and C) and mesentreric lymph^nodes (see line 106, fig.3B ). I t should be noted that there was no specific expression in the heart of line 106, and in the intestine, kidney, brain, heart and lung of line 91 (results ppCTM i s transiently expressed in foetal l i v e r During mouse ontogeny, B-^cell production begins in the l i v e r , where i t reaches a peak around 17 days of foetal l i f e and ceases several days after b i r t h . We have measured both < light-»chain mRNA and specific ppCTM transcript tion In the l i v e r , spleen, thymus and intestine of line 106 at various stages of ontogeny (see < CONST and CON respectively in f i g . 4 ) . < light^chain RNA was just detectable in the liver of 14 day embryos (E14), increased in 16 and 18 day embryos (E16, E18) reached a peak 2 days (2d) after birth and then decreased so that by 4 days after birth i t had declined to the low level found in adult l i v e r . In contrast, in the spleen, both < light-K;hain mRNA and ppCTM transcription increased with age and were highest in the 20 day old mouse. I t is noteable that there was more ppCTM expression in the l i v e r than in the spleen at 18 days of foetal l i f e . In the intestine and the thymus both K and ppCTM expression were always low, although both increased slightly and in parallel with age. These results show that ppCTM expression parallels B^-cell development in the foetal l i v e r .
RESULTS
Establishment of transgenic lineages
The Ig K promoter can efficiently substitute for the conalbumin promoter for specific expression in B^cells To try to increase specific expression of our hybrid recombinants we replaced the conalbumin promoter, which Is poorly active in mouse c e l l s , with the mouse Ig K promoter (pp<M). RNA from transgenic lines was analyzed with a 5'[ 32 P] labelled 330 bp SfaNI ONA fragment ( f i g .
) . RNA i n i t i a t e d from the K
promoter results in a SI resistant product labelled K PROM ( f i g . 5 ) . From four transgenic l i n e s , three preferentially expressed the transgene in the spleen ( f i g . 5 ) . The fourth line (n°12) did not show any expression in the tissues tested. In the three positive mouse lines no expression at a l l was detected in kidney, brain and reticulocytes. Expression 1n the lung can be correlated with the contamination of this tissue by lymphs-nodes as i t parallels that of the i c light-^chain gene. However, expression in the intestine, which contains numerous lymph follicules in i t s wall, was highly variable from line to line (high, intermediate or very low in lines 31,26 and 50 respectively). Unexpec* ted expression, different for each l i n e , was obtained in liver (line 26), testes (line 31) or thymus (line 50), which is clearly not correlated with < 11ght-*chain RNA transcription. The amount of transgenic RNA In the spleen was measured relative to K RNA using < promoter and < constant region SI nuclease probes of known specific a c t i v i t y . In a l l three positive lines there was about 50 times less pp*M RNA than endogenous K 11 ght->chain gene mRNA (results not shown, see f i g . l last column), which is a higher level of expression than was found with the conalbumin promoter (see above). These results suggest that the Ig < promoter increases the efficiency of specific gene expression.
DISCUSSION
The IgH enhancer Is specifically active in splenic B*cel1s In transgenic mice The hybrid gene consisting of a chicken conalbumin promoter element (+62 to *102) and the rabbit p*globin structural gene (ppCT) gave no detectable mRNA in a variety of tissues, including liver and reticulocytes, in 5 trans* genie mouse lines. This result was not predictable for a number of reasons. ppCT is specifically transcribed, albeit at low level, after transfection in several mouse cell •'lines (22; B. Wasylyk and C. Wasylyk, unpublished results). Transfection studies in mouse erythroleukemia cells show that sequences downstream from the translation initiation codon can regulate expression from foreign promoter elements (9, 10) . In transgenic mice, 48 bp of 5 1 flanking sequence are sufficient for specific p*glob1n expression (23) and the chicken conalbumin gene has been reported to be specifically expressed in the liver of transgenic mice (24) . Our results suggest that the rabbit p*globin structural gene and the conalbumin promoter element, when linked in ppCT, are poorly active when reintroduced into the mouse genome.
The IgH enhancer 1n ppCTM specifically stimulated transcription in B*cells. Recently Adams et al. (25) showed that the c*myc oncogene linked to the IgH enhancer specifically induced malignency in B*cells. Although in this case the oncogene might have contributed to the B*cell specificity, taken together with our results, we can conclude that the IgH enhancer is most active in B*cells. This agrees with some experiments using mouse cell* linesMason et al. (21) found in transfection experiments that the IgH enhancer showed no detectable activity in several T*cell lymphomas. Ephrussi et al. (26) observed, using dimethyl sulphate modification of DNA in chromatin, that certain guanine residues in the enhancer region exhibited altered reacti* vities in cells of the B*cell lineage, but not in non*lymphoid cell*lines or or in several T cell*lines. In contrast, in some T cell*lines, sterile transcripts have been observed initiated from cryptic promoters in the germ* line heavy*chain locus (27, 28) and in transgenic mice, the introduced rearranged IgH gene is efficiently expressed in both the thymus and in Lyt2+ T*cells (6). We did not detect IgH enhancer activity in either the thymus or In splenic T*cells (50% of which are normally Lyt2+) showing that the IgH enhancer is Inactive in most W e l l s . It seems likely that In the rearranged IgH gene, promoter sequences outside the enhancer are responsible for the transcriptional activity in T*cells. These promoter sequences may lie up* stream from the RNA initiation site or perhaps In the D*J region in which s t e r i l e transcripts i n i t i a t e in both pre B and T-cells (27, 29) .
The transgenes are less e f f i c i e n t l y expressed than the endogenous Ig genes ppCTM, containing the IgH enhancer and the conaibumin promoter, was expressed at a variable level in the spleen of three transgenic lines, at either 4%, 0.2% or 0.1% of the < light-chain mRNA (see f i g . l last column).
Assuming 7500 K mRNA molecules per spleen cell (30) Unexpected transgene expression in individual mouse lines. In many of the mouse lines we have observed transgene expression in a tissue which could not be accounted for by B-cell contamination, and which was stably inherited over several generations. This includes the liver of line 26 (PPKM), the testes of line 31 (pp<M), the thymus of line 50 (ppicM), the brain of line 71 (ppCTM) and probably the intestine of line 31 (pp<M). In line 31, expression in the intestine was consistently higher than expected from B-cells contamination (as judged from K mRNA) especially when compared to lines 26 and 50. Intestinal tissues contain Peyer's patches which comprise IgA producing lymphocytes. It is surprising that most lines (for pp*M and ppCTM), except line 31, do not express the transgene in the intestine, ever though a substantial amount of < gene transcription is detected. It is conceibable that the IgH enhancer is not active in IgA producing B lympho--cytes. Unexpected transgene expression has been observed previousy (4) and may result from integration in a region of the chromosome which is specifi--cally active in a given tissue. It may also arise from pBR322 sequences, which are known to influence gene expression in transgenic mice (23) . In addition, juxtaposition of control sequences from three different sources (the rabbit p-*globin sequences, the chicken conalbumin promoter and the mouse IgH enhancer) may have created a new specificity (35) . However, whatever the cause, the interesting observation was that aberrant expression was only found when the IgH enhancer was present in the recombinant. This agrees with other studies, which show that the IgH enhancer is active in certain condi--tions in non B-»cells (see 7). Perhaps new tissue specific genes and enhancers could be isolated by cloning host flanking sequences. Mouse line 106 (ppCTM) was found to have a reduced fertility and to be homozygous lethal before the 9th day of embryo development. The flanking host sequences have been cloned and experiments are in progress to study the site of integration.
In conclusion, we have developed a hybrid gene construction in which the specificity of the IgH enhancer can be studied in transgenic mice. A central core of the enhancer used in this study can efficiently stimulate transcript tion in non->-lymphoid cell»lines, such as mouse fibroblasts (7) and surrounding sequences contain cell-'type specific transcription inhibitory sequences (Imler et al., in preparation). Various mutants In the IgH enhancer are now being tested, using ppCT type recombinants in transgenic mice, to study the function of these sequences in both tissue specificity and B-"-cell differentiation.
